⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL37779 | 0.67 | — | — | |
| SCHEMBL57306 | 0.66 | — | — | |
| SCHEMBL8648295 | 0.66 | — | — | |
| SCHEMBL21954031 | 0.66 | HRH3 (0.38) | — | |
| SCHEMBL24590305 | 0.64 | SMN1; SMN2 (0.40) | — | |
| SCHEMBL5962431 | 0.64 | SMN1; SMN2 (0.40) | — | |
| Hydrochloric Acid SCHEMBL2139284 | 0.64 | PRKCG (0.40) | — | |
| Bromide SCHEMBL8912653 | 0.64 | HRH3 (0.37) | — | |
| SCHEMBL18085476 | 0.64 | SMN1; SMN2 (0.40) | — | |
| SCHEMBL21221329 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240101553-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-03-28 | — | — | US | claimed |
| US-20200262837-A1 | KRAS G12C INHIBITORS | ARRAY BIOPHARMA INC. | 2020-08-20 | — | — | US | claimed |
| US-10689377-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2020-06-23 | — | — | US | claimed |
| US-20190144444-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2019-05-16 | — | — | US | claimed |
| US-8653262-B2 | CCR2 receptor antagonists and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-18 | — | — | US | claimed |
| EP-0719273-B1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES INC (US) | 2010-11-03 | — | — | EP | claimed |
| EP-4339192-A2 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | The Regents of the University of California (US) | 2024-03-20 | — | — | EP | disclosed |
| EP-3478284-B1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | UNIV CALIFORNIA (US) | 2023-10-04 | — | — | EP | disclosed |
| US-20230150942-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-05-18 | — | — | US | disclosed |
| US-11560356-B2 | Compounds and compositions for the treatment of cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-01-24 | — | — | US | disclosed |
| CN-109661229-B | Compounds and compositions for the treatment of cancer | 加利福尼亚大学董事会 | 2022-06-28 | — | — | CN | disclosed |
| US-20210009523-A1 | Compounds and Compositions for the Treatment of Cancer | RASCAL THERAPEUTICS, INC. | 2021-01-14 | — | — | US | disclosed |
| EP-3478284-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | The Regents of The University of California (US) | 2019-05-08 | — | — | EP | disclosed |
| CN-108884070-A | PYRIDYL DERIVATIVES AS BROMODOMAIN INHIBITORS | 葛兰素史克知识产权第二有限公司 | 2018-11-23 | — | — | CN | disclosed |
| WO-2018005678-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-01-04 | — | — | WO | disclosed |
| EP-0844000-A1 | Use of alpha, omega-diarylalkane derivatives in the treatment and prevention of psychosis | SANKYO COMPANY LIMITED (JP) | 1998-05-27 | — | — | EP | disclosed |
| US-5556864-A | TREATMENT OF CIRCULATORY DISEASES AND PSYCHOSIS | SANKYO COMPANY, LIMITED (JP) | 1996-09-17 | — | — | US | disclosed |
| EP-0600717-A1 | Phenoxyalkylamines, -pyrrolidines and -piperidines for the treatment and prevention of circulatory diseases and psychosis | SANKYO COMPANY LIMITED (JP) | 1994-06-08 | — | — | EP | disclosed |